HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC

Future Oncology, Ahead of Print.

Source: Future Oncology - May 22, 2023 Category: Cancer & Oncology Authors: Helena A Yu James Chih-Hsin Yang   Hidetoshi Hayashi   Yasushi Goto   Enriqueta Felip Martin Reck   Michele Vigliotti Qian Dong Fr édérique Cantero Pang-Dian Fan   Masayuki Kanai David W Sternberg Pasi A J änne  Source Type: research